title: Improving outcomes in patients with psoriasis.
abstract: Psoriasis is a heterogeneous inflammatory disorder that targets the skin and joints. It affects 1.3-2% of the population. The diagnosis of plaque psoriasis is usually straightforward, a helpful diagnostic clue is the tendency for silver scales to appear after gentle scratching of a lesion. Stress, streptococcal infection and drugs including beta-blockers, antimalarials and lithium may precipitate or exacerbate psoriasis. Psoriasis, especially when severe, predisposes to metabolic syndrome, and patients with psoriasis are at increased risk of ischaemic heart disease, hypertension, stroke, type 2 diabetes and hyperlipidaemia. Additionally, psoriasis sufferers appear at increased risk of uveitis, inflammatory boweldisease, lymphoma, non-melanoma skin cancer, COPD and venous thromboembolism. Psoriasis should be assessed on the basis of: severity, impact on physical, psychological and social wellbeing, symptoms of arthritis and the presence of comorbidities. Poor response to topical therapy may be as much to do with lack of compliance as with lack of efficacy. The number of treatments each day should be kept to a minimum, and patients should be reviewed after four weeks when initiating or changing topical therapy to improve adherence to treatment and assess response. The majority of patients with psoriasis can be managed in primary care, although specialist care may be necessary at some point in up to 60% of cases. Patients with erythrodermic or generalised pustular psoriasis should be referred for a same day dermatological opinion, and if psoriatic arthritis is suspected, early referral for a rheumatological opinion is recommended.
authors.affiliation: Department of Dermatology, Royal Infirmary of Edinburgh, Edinburgh, UK.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Tidman
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000875:Anthralin / Q000008:administration & dosage; D065095:Calcineurin Inhibitors; D002117:Calcitriol / Q000008:administration & dosage; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D009539:Nicotinic Acids / Q000008:administration & dosage; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D011788:Quality of Life; D012720:Severity of Illness Index; D013638:Tars / Q000627:therapeutic use; D012176:Retinoids
chemical_list: D000305:Adrenal Cortex Hormones; D000875:Anthralin; D065095:Calcineurin Inhibitors; D002117:Calcitriol; D003879:Dermatologic Agents; D009539:Nicotinic Acids; D013638:Tars; C086827:tazarotene; D012176:Retinoids